Causes and consequences of aberrant mRNA translation in cancer
This project aims to investigate aberrant mRNA translation in cancer due to amino acid shortages, linking it to tumor progression and developing novel therapeutic strategies.
Projectdetails
Introduction
Shortages in amino acids are weapons in the warfare between tumor cells and tumor-infiltrating lymphocytes. Tumor cells enhance or inhibit the production of key amino acid metabolites to stimulate oncogenesis and suppress anti-tumor activity. A key player in this battle is tryptophan.
Mechanism of Action
Activated T cells secrete interferon-γ, which upregulates the IDO1 enzyme to catabolize tryptophan to kynurenine in target tumor cells. While kynurenine suppresses T-cell function, its production limits tryptophan availability in tumor cells.
Consequences of Tryptophan Shortage
Importantly, as tumor cells almost invariably deregulate mRNA translation to promote proliferation and metastasis, the consequences of tryptophan shortage are major. It provokes aberrant mRNA translation at tryptophan codons, resulting in:
- Ribosomal frameshifting
- Tryptophan to phenylalanine (W>F) codon reassignments (substitutants)
This aberrant mRNA translation alters protein function and enriches the landscape of neoepitopes at the surface of tumor cells. Based on these observations, I hypothesize that the detection of aberrant proteins in cancer specimens can reveal additional key processes of cancer progression beyond tryptophan that can be utilized for cancer therapy.
Work Packages
To explore this exciting new idea, I designed three work packages (WPs):
-
WP1: Expand the landscape of aberrant mRNA translation in cancer and link them to cancerous events. Preliminary results pinpoint arginine, histidine, and leucine.
-
WP2: Generate reporter assays, set up functional genetic screens, and identify, validate, and explore key regulators of aberrant mRNA translation.
-
WP3: Study the functional consequences of aberrant mRNA translation and introduce novel therapeutic concepts.
Conclusion
Altogether, this proposal will employ our recent discoveries of aberrant mRNA translation during periods of amino acid shortages to explore novel interplays between cancers and their suppressive microenvironment, and utilize this new knowledge for cancer therapy.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 2.500.000 |
Totale projectbegroting | € 2.500.000 |
Tijdlijn
Startdatum | 1-9-2024 |
Einddatum | 31-8-2029 |
Subsidiejaar | 2024 |
Partners & Locaties
Projectpartners
- STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUISpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Targeting the Metabolic Dependencies of Metastatic Tumor CellsThis project aims to identify and target unique amino acid dependencies in metastatic melanoma cells to develop novel therapies that prevent metastasis and improve cancer treatment outcomes. | ERC Starting... | € 1.493.750 | 2024 | Details |
Unraveling Ribosome Heterogeneity: Implications for Metastasis and BeyondThis project aims to map ribosomal heterogeneity in metastatic cancers to uncover how specialized ribosomes influence oncogenic translation and metastasis, potentially identifying new cancer biomarkers and therapies. | ERC Starting... | € 1.500.000 | 2025 | Details |
Species-specific aspects in eukaryotic mRNA translation modulation and their implications in diseasesThis project aims to investigate species-specific mRNA translation mechanisms in mammals and kinetoplastid parasites to inform new treatments for diseases like cancer and infections. | ERC Consolid... | € 1.999.539 | 2023 | Details |
Setting the optimal balance between metabolite supplementation and deprivation in cancer therapyThis project aims to combine targeted metabolite supplementation with global nutrient restriction to reprogram tumor metabolism, enhance treatment response, and improve survival in advanced triple-negative breast cancer patients. | ERC Starting... | € 1.499.250 | 2023 | Details |
An integrative genetic approach for the exploration of melanoma immunological interactionsThis project aims to enhance cancer vaccine efficacy by systematically analyzing the immunopeptidome in melanoma to identify actionable neopeptides and their impact on immune responses. | ERC Advanced... | € 2.500.000 | 2023 | Details |
Targeting the Metabolic Dependencies of Metastatic Tumor Cells
This project aims to identify and target unique amino acid dependencies in metastatic melanoma cells to develop novel therapies that prevent metastasis and improve cancer treatment outcomes.
Unraveling Ribosome Heterogeneity: Implications for Metastasis and Beyond
This project aims to map ribosomal heterogeneity in metastatic cancers to uncover how specialized ribosomes influence oncogenic translation and metastasis, potentially identifying new cancer biomarkers and therapies.
Species-specific aspects in eukaryotic mRNA translation modulation and their implications in diseases
This project aims to investigate species-specific mRNA translation mechanisms in mammals and kinetoplastid parasites to inform new treatments for diseases like cancer and infections.
Setting the optimal balance between metabolite supplementation and deprivation in cancer therapy
This project aims to combine targeted metabolite supplementation with global nutrient restriction to reprogram tumor metabolism, enhance treatment response, and improve survival in advanced triple-negative breast cancer patients.
An integrative genetic approach for the exploration of melanoma immunological interactions
This project aims to enhance cancer vaccine efficacy by systematically analyzing the immunopeptidome in melanoma to identify actionable neopeptides and their impact on immune responses.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Novel peptide-based therapeutics for reprogramming the tumour stroma extracellular matrix using molecular modelling and computational engineeringThe project aims to develop TAX2, a novel peptide therapy targeting the tumor microenvironment to inhibit solid tumor progression and enhance immunotherapy efficacy, with a focus on ovarian cancer. | EIC Accelerator | € 2.434.790 | 2025 | Details |
Novel peptide-based therapeutics for reprogramming the tumour stroma extracellular matrix using molecular modelling and computational engineering
The project aims to develop TAX2, a novel peptide therapy targeting the tumor microenvironment to inhibit solid tumor progression and enhance immunotherapy efficacy, with a focus on ovarian cancer.